Pan-Immune-Inflammation Value Meta-Analysis for Cardiovascular Risk After PCI

A systematic review and meta-analysis synthesizing evidence on the pan-immune-inflammation value (PIV) as a prognostic biomarker. The work aggregates data from 19 cohort studies involving 18,715 patients with acute coronary syndrome undergoing percutaneous coronary intervention. It was authored by Xinrui Yin and published on figshare in 2026.

Use Cases

• Validate the prognostic value of the pan-immune-inflammation value (PIV) for major adverse cardiovascular events (MACE).
• Assess the discriminatory power of PIV for angiographic no-reflow or slow-flow outcomes.
• Compare the performance of PIV against established inflammatory indices like GRACE or TIMI scores.
• Investigate associations between integrated immune cell counts and post-contrast renal injury risk.

Strengths

• Aggregates data from 19 cohort studies with a total of 18,715 patients.
• Reports pooled hazard ratios and AUC values with confidence intervals for multiple outcomes.
• Includes a detailed risk-of-bias assessment using the QUIPS tool and certainty rating with GRADE.

Limitations

• The dataset is a PDF document (298.3 KB) containing a review article, not a primary data table; row and column counts are unknown.
• Evidence is limited by observational study designs, heterogeneous cut-offs, and a small number of studies for several outcomes.
• Column-level documentation for any underlying data is absent; field semantics must be inferred from the article text.

Provenance

Source

figshare

Collection Method

Systematic literature review and meta-analysis of published cohort studies.

Time Range

Studies searched from database inception to the date of the review.

Freshness

Last updated 2026-06-01 08:29:28.